Learning Impairments Among Survivors of Childhood Cancer

• Status: Completed
• Trial end date: 2010-03-01
• Target enrollment: 0
• Participant gender: All

Summary

Children surviving some types of cancer have a higher risk of developing learning problems after cancer treatment than do children who have not had cancer or its treatment. Cancer treatment may cause problems with learning, attention, and memory. The purpose of this study is to identify brain changes that may underlie learning problems in cancer survivors and investigate whether methylphenidate (a stimulant medication) may reduce these problems.

Subjects who have had treatment for acute lymphoblastic leukemia (ALL) or a brain tumor will be asked to take part in this research study. Siblings of some subjects will also be asked to take part, so that their results can be compared with those of children who have had cancer treatment. We hypothesize that children receiving more aggressive therapy will have lower white matter brain volumes and these volumes will be significantly lower than age-matched siblings. We also hypothesize that children who take methylphenidate will show improvements on teacher and parent report measures of attention and social skills.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: St. Jude Children's Research Hospital
• Collaborator: National Cancer Institute (NCI)
• Treatments: Methylphenidate

Criteria

Inclusion Criteria:

• Age: 6 to 18 years old.

• Active subject at St. Jude Children's Research Hospital, or is an age-matched sibling control subject.

• If a subject, received treatment for brain tumor or ALL with either radiation therapy and/or chemotherapy directed at the brain.

• If a subject, at least 12 months post-completion of antineoplastic therapies

• If a subject, no evidence of malignancy, or continuously stable disease since completion of therapy

• English as a primary language

• Informed consent

Exclusion Criteria:

• Glaucoma

• Patient or immediate family member with a history of Tourette's syndrome

• Current antidepressant, anxiolytic, antipsychotic or stimulant therapy

• History of substance abuse

• Recent history of uncontrolled seizures

• Uncorrected hypothyroidism

• Previously or currently randomized on COGRM1 intervention arm

• Previously diagnosed with ADHD, or, if a patient, diagnosed with ADHD prior to diagnosis of malignancy